

# Antoine Leuzy

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9356376/publications.pdf>

Version: 2024-02-01

14  
papers

2,035  
citations

777949

13  
h-index

1113639

15  
g-index

15  
all docs

15  
docs citations

15  
times ranked

2659  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Blood-based biomarkers for Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2022, 14, e14408.   | 3.3 | 122       |
| 2  | Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. <i>Nature Aging</i> , 2021, 1, 114-123.                                  | 5.3 | 94        |
| 3  | The strategic biomarker roadmap for the validation of Alzheimer's diagnostic biomarkers: methodological update. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2070-2085. | 3.3 | 22        |
| 4  | Plasma biomarkers of Alzheimer's disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. <i>Nature Communications</i> , 2021, 12, 3555.                           | 5.8 | 115       |
| 5  | A multicentre validation study of the diagnostic value of plasma neurofilament light. <i>Nature Communications</i> , 2021, 12, 3400.   | 5.8 | 219       |
| 6  | The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 1145-1156.   | 0.4 | 174       |
| 7  | Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease. <i>Brain</i> , 2020, 143, 3793-3804.  | 3.7 | 60        |
| 8  | Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 772.                 | 3.8 | 640       |
| 9  | Optimal timing of tau pathology imaging and automatic extraction of a reference region using dynamic [18F]THK5317 PET. <i>NeuroImage: Clinical</i> , 2019, 22, 101681.                                   | 1.4 | 2         |
| 10 | Clinical impact of [18F]flutemetamol PET among memory clinic patients with an unclear diagnosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1276-1286.                | 3.3 | 38        |
| 11 | Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1152-1163.        | 3.3 | 30        |
| 12 | Tau PET imaging in neurodegenerative tauopathies is still a challenge. <i>Molecular Psychiatry</i> , 2019, 24, 1112-1134.  | 4.1 | 409       |
| 13 | Tau positron emission tomography imaging in tauopathies: The added hurdle of off-target binding. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 232-236.      | 1.2 | 86        |
| 14 | Detection of Alzheimer's Disease. <i>Yale Journal of Biology and Medicine</i> , 2018, 91, 291-300.   | 0.2 | 21        |